Gout Disease Treatment Market, by Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate-lowering Agents, and Monoclonal Antibody), by Route of  Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

  • Published On : Nov 2019 |
  • Pages : 182 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Gout Disease Treatment Market Insights

Gout is the condition that is characterized by formation of excess of uric acid in body tissues that results in the formation of crystals of monosodium urate. Symptoms of gout includes intense pain, swelling, and stiffness in the joints. The progression stages of gout includes asymptomatic hyperuricemia (gout), acute gout, interval or intercritical gout, chronic tophaceous gout, and pseudogout. Anti-gout drugs are available in oral and injectable dosage form. Orally administered drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, and colchicine are equally effective in the treatment of acute gout. Most of the major brands such as Zurampic, Duzallo, Zyloprim, Celebrex, and Voltaren are available in oral dosage form in the market. Thus, availability of such orally administered drugs is expected to drive growth of global gout disease treatment market over the forecast period.

The global gout disease treatment market was valued at US$ 2,385.7 million in 2018, and is expected to exhibit a CAGR of 6.7% during the forecast period (2019–2027).

Figure 1. Global Gout Disease Treatment Market Share (%), By Drug Class

Gout Disease Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing research and development activities, in order to develop novel treatment approach for gout disease and regulatory approval for the anti-gout drugs are expected to be a major factor driving growth of the global gout disease treatment market over the forecast period

 

Increasing pipeline studies to develop novel anti-gout drugs is expected to drive the global gout disease treatment market growth over the forecast period. For instance, Arthrosi Therapeutics, will initiate phase 2 clinical trial study in December 2019 to evaluate the pharmacodynamics and pharmacokinetic profile, safety, and tolerability of AR882 (drug candidate) alone or in combination with febuxostat or allopurinol, when administered to gout patients. The study is estimated to be completed by June 2020.

Moreover, increasing product approvals by regulatory authority is expected to drive growth of the gout disease treatment market. For instance, in December 2018, SunGen Pharma, a privately held company, received the U.S. FDA approval for Prednisone (generic version of Deltasone), a drug with various strengths 10 mg, 20 mg, and 50 mg tablets to treat various conditions such as arthritis, gout, blood disorders, immune system disorders, and others.

Penetration of generic version of anti-gout drugs is expected to provide growth opportunities to market players, in order to increase their share in gout disease treatment market.

Adverse effects and risks associated with drugs such as NSAIDs and urate-lowering agents is expected to hamper the global gout disease treatment market growth

Most of the gout drugs are associated with severe side effects, which is expected to decrease demand for these drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause some gastric problems such as indigestion. In few cases, these drugs can cause gastric ulcers, bleeding, and rashes in gastrointestinal (GI) tract. Moreover, side effects such as intolerability and contraindication is expected to limit the usage of these drugs in treatment of gout. For instance, in February 2019, the U.S. Food and Drug Administration (FDA) has added a new boxed warning for febuxostat, due to increased risk of death associated with Uloric (febuxostat) compared to other gout medicine, allopurinol. Febuxostat belongs to the urate-lowering agents.

Global Gout Disease Treatment Market- Regional Analysis

Based on region, the global gout disease treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to hold a dominant position in the market, owing to presence of major players and non-profit organizations in the region. These market players and non-profit organizations are focused on launching new programs and awareness campaigns to educate people about gout disease and help healthcare practitioners in the treatment of gout disease. For instance, in May 2016, Takeda Pharmaceuticals U.S.A., Inc. and Arthritis Foundation launched a program, Let’s Speak Gout, based on new joint research to enhance disease management in patients with gouty arthritis.

Moreover, Europe gout disease treatment market is expected to exhibit significant growth over the forecast period, owing to increasing regulatory approval of the products indicated for the treatment of gout disease. For instance, in August 2018, Grünenthal GmbH received marketing authorization from European Union for its product Duzallo (Allopurinol and Lesinurad), a fixed-dose combination (FDC) therapy indicated for the treatment of hyperuricaemia in adult gout patients. The marketing authorization was granted for 28 European Union member states and European Economic Area (EEA) countries, Norway, Iceland, and Liechtenstein.

Figure 2: Global Gout Disease Treatment Market Share (%), By Region

Gout Disease Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Global Gout Disease Treatment Market - Competitive Landscape

Key players operating in the global gout disease treatment market include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Novartis International AG, Teijin Pharma Limited, Simcere Pharmaceutical, JW Pharmaceutical Corporation, Horizon Therapeutics Plc., Hikma Pharmaceuticals Plc, Ironwood Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., and Zyla Life Sciences (Pty) Ltd.,

Gout is the chronic disease characterized by pain and inflammation in the joint. It is also known as gout arthritis, in which high level of uric acid in blood leads to formation of the needle-like crystals in the joints resulting into inflammation and pain. The conditions can be treated or prevented with use of the drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents. Moreover, monoclonal antibody is also used to treat gout for certain cases in which, nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate lowering agents are unresponsive to the patient.

Market Dynamics

Increasing prevalence of gout disease is expected to increase demand of anti-gout drugs, which is expected to drive growth of the gout disease treatment market growth in forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) (Rheumatology journal), the prevalence of gout in 2015 increased in South Korea compared to 2007 (earlier reported prevalence). In 2007, the prevalence of gout disease in South Korea was 3.49 (3.48-3.51) per 1,000 persons and in 2015, the prevalence of gout disease in South Korea was 7.58 (7.55-7.60) per 1,000 persons. Moreover, according to the data from the Australian Bureau of Statistics 2017–2018 (a National Health Survey), an estimated 187,000 people of Australia (0.8% of the Australia population) were diagnosed with gout disease in 2017.

Key features of the study:

  • This report provides in-depth analysis of the global gout disease treatment market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2019 – 2027), considering 2018, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrixes for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global gout disease treatment market based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Novartis International AG, Teijin Pharma Limited, Simcere Pharmaceutical, JW Pharmaceutical Corporation, Horizon Therapeutics plc., Hikma Pharmaceuticals Plc, Ironwood Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., and Zyla Life Sciences
  • Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future technology launches, governmental initiatives, technological up-gradation, market expansions, and marketing tactics
  • The global gout disease treatment market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global ophthalmic viscoelastic devices industry, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Gout Disease Treatment Market, By Drug Class:
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Corticosteroids
    • Colchicine
    • Urate-lowering Agents
    • Monoclonal Antibody
  • Global Gout Disease Treatment Market, By Route of Administration:
    • Oral
    • Injectable
  • Global Gout Disease Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Gout Disease Treatment Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
        • Monoclonal Antibody
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
        • Monoclonal Antibody
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
        • Monoclonal Antibody
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
        • Monoclonal Antibody
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
        • Monoclonal Antibody
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
        • Monoclonal Antibody
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • AstraZeneca Plc*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Takeda Pharmaceutical Company Limited
    • Novartis International AG
    • Teijin Pharma Limited
    • Simcere Pharmaceutical
    • JW Pharmaceutical Corporation
    • Horizon Therapeutics plc
    • Hikma Pharmaceuticals Plc.
    • Ironwood Pharmaceuticals, Inc.
    • CymaBay Therapeutics, Inc.
    • Zyla Life Sciences

“*” marked represents similar segmentation in other categories in the respective section

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Mergers and Acquisitions
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
    • Epidemiology
  4. Global Gout Disease Treatment Market, By Drug Class, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Colchicine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million) Corticosteroids
    • Urate-lowering Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Monoclonal Antibody
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  5. Global Gout Disease Treatment Market, By Route of Administration, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Injectable
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Gout Disease Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Gout Disease Treatment Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Takeda Pharmaceutical Company Limited  
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teijin Pharma Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Simcere Pharmaceutical
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • JW Pharmaceutical Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Horizon Therapeutics plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Hikma Pharmaceuticals Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Ironwood Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Zyla Life Sciences.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • CymaBay Therapeutics, Inc..
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 32 market data tables and 35 figures on "Gout Disease Treatment Market” - Global forecast to 2027”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.